Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozoralizumab - Ablynx/Eddingpharm/Taisho

Drug Profile

Ozoralizumab - Ablynx/Eddingpharm/Taisho

Alternative Names: ATN-103; PF-05230896; PF5230896; TS-152

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx
  • Developer Ablynx; Eddingpharm; Pfizer; Taisho Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Proteins
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Discontinued Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis

Most Recent Events

  • 31 Aug 2018 Ozoralizumab is available for licensing (excluding Japan, China, Hong Kong, Macau, Taiwan) as of 31 Aug 2018. http://www.ablynx.com/
  • 01 Aug 2018 No development reported - Preclinical for Rheumatoid arthritis in China (SC) (Taisho Pharmaceutical pipeline, August 2018)
  • 01 Aug 2018 Phase-III clinical trials in Rheumatoid arthritis in Japan (SC) (Taisho Pharmaceutical pipeline, August 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top